Excerpt of Deposition of Patrick Miles, Taken November 8, 2010

NON-CONFIDENTIAL

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF CALIFORNIA

WARSAW ORTHOPEDIC, INC.,

Plaintiff,

CASE NO.

vs.

3:08-CV-01512-MMA (AJB)

NUVASIVE, INC.,

Defendant.

NUVASIVE, INC.,

Counterclaimant,

vs.

MEDTRONIC SOFAMOR DANEK
U.S.A., INC.; WARSAW
ORTHOPEDIC, INC.; MEDTRONIC
PUERTO RICO OPERATIONS CO.,
and MEDTRONIC SOFAMOR DANEK
DEGGENDORF, GmbH,

Counterclaim Defendants.

AND RELATED COUNTERCLAIMS

CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE

VIDEOTAPE DEPOSITION OF PATRICK MILES

MERRILL CORPORATION

LegaLink, Inc.

20750 Ventura Boulevard Suite 205 Woodland Hills, CA 91364 Phone: 818.593.2300 Fax: 818.593.2301

| | | |
|-----------------------|----|--|
| | | RMATION - PATENT PROSECUTION SENSITIVE MILES - 11/8/2010 |
| | | Page 31 |
| 11:12:29 | 1 | A Several. |
| 11:12:31 | 2 | Q Name them. |
| 11:12:38 | 3 | A Myself. That's the one I most recollect. |
| 11:12:53 | 4 | Q You don't recall anyone else designing the |
| 11:12:56 | 5 | CoRoent XL? |
| 11:12:57 | 6 | A Do I remember the specific individuals who were |
| 11:13:02 | 7 | designers on the on the project? I don't remember |
| 11:13:05 | 8 | every individual who touched it. |
| 11:13:08 | 9 | Q Do you recall whose idea it was to develop the |
| 11:13:10 | 10 | CoRoent XL? |
| 11:13:15 | 11 | A Do I remember whose idea it was to develop the |
| 11:13:17 | 12 | CoRoent XL? |
| 11:13:19 | 13 | MR. MILLER: Let me just object. That question |
| 11:13:21 | 14 | is also beyond the scope of the noticed topic. |
| 11:13:24 | 15 | To the extent you know the answer, you can say. |
| 11:13:26 | 16 | BY MS. WICKRAMASEKERA: |
| 11:13:37 | 17 | Q You can answer the question. |
| 11:13:44 | 18 | A Are you asking me who was part of the design? |
| 11:13:49 | 19 | Q Yes. Who was part of the initial design |
| 11:13:51 | 20 | efforts on the CoRoent XL? |
| 11:13:53 | 21 | A There are multiple individuals, of which I |
| 11:13:55 | 22 | cannot recall all of them, nor can I recall what their |
| 11:14:00 | 23 | specific input was on the device. |
| 11:14:02 | 24 | Q Can you recall any of them? |
| 11:14:12 | 25 | A Scott Martineli. |
| Merrill 800-826-02 | | poration - Los Angeles www.merrillcorp.com/law |

CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010

Page 30

```
11:11:24
                        noticed topic.
   11:11:26
                            THE WITNESS: First conceived?
   11:11:27
                        BY MS. WICKRAMASEKERA:
   11:11:28
                         Q Yes.
   11:11:29
                         A I don't know.
   11:11:35
                          Q When did design efforts first begin on the
   11:11:38
                       CoRoent XL?
   11:11:40
                 8
                            MR. MILLER: Objection; asked and answered.
   11:11:45
                            THE WITNESS: At some point between 2002 and
   11:11:47
                10 2004.
   11:11:48
                11
                        BY MS. WICKRAMASEKERA:
   11:11:48
                12
                          Q So you don't know at what point between 2002
   11:11:52
                        and 2004 the CoRoent XL first began in the design phase?
                          A It was greater than eight years ago. It's not
   11:11:57
                  14
   11:12:00
                  15
                        something that I pull and reflect.
   11:12:03
                  16
                          Q Is this something that you prepared on to
   11:12:06
                  17
                        provide your corporate testimony today?
   11:12:07
                  18
                          A No.
   11:12:11
                  19
                          Q\quad Who \ designed \ the \ CoRoent \ XL?
                          A Who designed the CoRoent XL?
                  20
   11:12:14
                          Q Yes.
   11:12:16
                  21
                          A What do you mean by who designed the
   11:12:20
                  2.2
   11:12:23
                  23
                       CoRoent XL?
   11:12:25
                  24
                          Q Which individuals were involved with designing
   11:12:27
                        the CoRoent XL?
Merrill
                                         - Los Angeles
                 Corporation
800-826-0277
                                     www.merrillcorp.com/law
```

CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 35 11:18:23 1 possibly fall within the scope of your topics. The 11:18:26 2 parties had an agreement that prior to 30(b)(6) 11:18:30 depositions, if any specific inquiries were to be made, 11:18:34 the documents would be produced. We received no 11:18:37 documents. So there was nothing for Mr. Miles to review 11:18:41 other than the entirety of NuVasive's document archives 11:18:44 which he was not going to do and has no obligation to 11:18:47 11:18:48 BY MS. WICKRAMASEKERA: 11:18:48 10 Q Mr. Miles, who were the NuVasive employees that 11:18:51 11 were involved with development of the CoRoent 11:18:53 12 XL-Standard? 11:18:57 13 A To the best of my recollection, it would be 11:19:01 14 Scott Martineli, Eric Finley, Matt Curran, Jared 11:19:20 15 Arambula, Laetitia Cousins. It's such a broad question. 11:19:35 16 There's so many people who were associated with the 11:19:38 17 design and development of the -- of the product that I 11:19:41 18 can't begin to name them all. 11:19:44 19 Q Why did NuVasive design the CoRoent 11:19:47 20 XL-Standard? 11:19:53 21 MR. MILLER: Objection; overbroad and vague. 11:19:55 22 Go ahead. 11:19:56 23 THE WITNESS: Why? 11:19:56 24 BY MS. WICKRAMASEKERA: 11:19:57 25 Q Yes. Merrill Corporation Los Angeles 800-826-0277 www.merrillcorp.com/law CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 36 11:19:58 1 A To fulfill a clinical obligation. 11:20:03 Q And what was that clinical obligation? 11:20:06 A Spine surgery -- it's a spine surgery device, 11:20:10 and the clinical obligation was to restore the --11:20:15 restore the disc height. 11:20:18 Q Was the CoRoent XL-Standard designed 11:20:20 7 specifically for lateral access surgery? 11:20:23 8 A Yes. 11:20:30 Q And what --11:20:30 10 A Specifically for XLIF. 11:20:31 11 Q Specifically. So the CoRoent XL-Standard was designed specifically for XLIF? 11:20:36 12 11:20:38 13 A Uh-huh. Q And just for the record, could you tell me what 11:20:38 14 11:20:41 15 XLIF stands for? 11:20:42 16 A EXtreme Lateral Interbody Fusion. 11:20:46 17 Q And who came up with the name XLIF? 11:20:48 18 MR. MILLER: Objection; beyond the scope of the 11:20:50 19 noticed topics. Counsel, if you could tell me which 11:20:53 2.0 topics you're going to be inquiring about, that would 11:20:55 21 help me either making or not objections to scope. 11:21:00 2.2 MS. WICKRAMASEKERA: I'm still on topic 2 and 11:21:02 23 XLIF is an accused product. 11:21:03 24 MR. MILLER: We went over to 30 and now we're 11:21:04 back to 2? 25 Merrill Corporation - Los Angeles 800-826-0277 www.merrillcorp.com/law

CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 39 11:23:37 1 MR. MILLER: Then it's beyond the scope. BY MS. WICKRAMASEKERA: 11:23:38 11:23:38 3 Q You can answer the question. 11:23:40 MR. MILLER: If you know in your individual 11:23:42 capacity, you can answer the question. 11:23:44 6 THE WITNESS: Please repeat the question. 11:23:45 BY MS. WICKRAMASEKERA: Q The CoRoent XL-Standard comes in a range of 11:23:46 8 9 lengths from 40 to 60 millimeters in 5-millimeter 11:23:49 11:23:54 10 increments; is that right? 11:24:21 11 It's not a guessing game. I'll make this 11:24:23 12 easier on you. I'm handing you what's been previously 11:24:31 1.3 marked as Ozgur Exhibit 9. 11:24:40 14 A I don't understand by the guessing game 11:24:42 15 comment. What's that mean? 11:24:43 16 Q I meant that I wasn't asking you to remember 11:24:47 17 the lengths. I can help you out by giving you a 11:24:50 18 document. 11:24:51 19 A You know, what you don't understand is that 11:24:53 20 they've been different lengths over different times. So 11:24:55 21 I was trying to answer the specificity of your question 11:24:59 22 rather than speculate. 11:25:00 23 Q I see. Okay. So what was the first range of 11:25:02 24 lengths the CoRoent XL-Standard came in? 11:25:05 A It was 40. Merrill Corporation Los Angeles 800-826-0277 www.merrillcorp.com/law CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 40 MR. MILLER: And the question is beyond the 11:25:06 11:25:07 scope of the noticed topic. THE WITNESS: Okay. 11:25:09 3 11:25:12 BY MS. WICKRAMASEKERA: 11:25:13 Q You can answer the question. 11:25:14 6 A What's the question? 11:25:16 Q What is the first range of lengths the CoRoent 11:25:18 8 XL-Standard came in? 11:25:20 A 40 and 45. 11:25:28 10 O And why did the CoRoent XL-Standard come in 11:25:32 11 lengths 40 and 45 initially? 11:25:34 12 MR. MILLER: Objection; beyond the scope of the 11:25:36 13 noticed topics. 11:25:39 14 THE WITNESS: Because that was the defined 11:25:41 15 requirement. 11:25:41 BY MS. WICKRAMASEKERA: 16 11:25:42 17 O And who defined the requirement for the lengths 11:25:44 18 that the CoRoent XL-Standard would come in? 11:25:47 19 A I did 11:25:47 20 MR. MILLER: Just, Mr. Miles, if you can pause 11:25:49 21 before you answer so I can interpose an objection. 11:25:52 22 My objection to the last question, it's beyond 11:25:54 23 the scope of topic 2. 11:25:57 24 BY MS. WICKRAMASEKERA: 11:26:01 Q Now I'm referring specifically to the range of Merrill Corporation -Los Angeles 800-826-0277 www.merrillcorp.com/law

| CONFIDENTIA | L INFO | RMATION - PATENT PROSECUTION SENSITIVE | CONFIDENTI | AL INFO | RMATION - PATENT PROSECUTION SENSITIVE |
|--|---|--|--|---|--|
| PATE | RICK | MILES - 11/8/2010 | PAT | RICK | MILES - 11/8/2010 |
| | | Page 41 | | | Page 43 |
| 11:26:04 | 1 | lengths that the CoRoent XL-Standard was first designed | 11:29:16 | 1 | specifics. |
| 11:26:08 | 2 | in. On what basis did you determine that the CoRoent | 11:29:33 | 2 | Q You testified that NuVasive designed the |
| 11:26:11 | 3 | XL-Standard should come in 40 and 45 millimeters? | 11:29:36 | 3 | CoRoent XL-Standard initially in 40 and 45 millimeters |
| 11:26:22 | 4 | A Repeat the question, please. | 11:29:40 | 4 | to make for the largest possible implant delivered. Did |
| 11:26:23 | 5 | Q Referring specifically to the range of lengths | 11:29:44 | 5 | you mean the largest possible implant delivered |
| 11:26:25 | 6 | that the CoRoent XL-Standard was first designed in, on | 11:29:47 | 6 | laterally? |
| 11:26:29 | 7 | what basis did NuVasive determine that the CoRoent | 11:29:49 | 7 | A You mischaracterized my comments. |
| 11:26:32 | 8 | XL-Standard should come in 40 and 45 millimeters? | 11:29:52 | 8 | Q Can you explain explain to me what you |
| 11:26:36 | 9 | MR. MILLER: The question is beyond the scope | 11:29:53 | 9 | meant? |
| 11:26:38 | 10 | of the noticed topic. If you can answer it, you may. | 11:29:54 | 10 | A I didn't I didn't say that. |
| 11:26:41 | 11 | Also overbroad. Also overbroad, I'm sorry. | 11:30:02 | 11 | Q When you testified that you were designing the |
| 11:26:54 | 12 | THE WITNESS: So repeat the question one more | 11:30:05 | 12 | largest implant possible, what did you mean? |
| 11:26:56 | 13 | time. | 11:30:10 | 13 | A I meant the largest footprint. |
| 11:26:56 | 14 | BY MS. WICKRAMASEKERA: | 11:30:19 | 14 | Q And by footprint, you specifically mean how it |
| 11:26:56 | 15 | Q Sure. Let me be a little more clear then. | 11:30:22 | 15 | rests on the vertebra? |
| 11:27:00 | 16 | Why did NuVasive first design the CoRoent | 11:30:26 | 16 | A I mean the amount of space it takes up as it |
| 11:27:02 | 17 | XL-Standard in 40 and 45-millimeter lengths? | 11:30:29 | 17 | relates to the vertebra. |
| 11:27:08 | 18 | A To maximize the implant footprint. | 11:30:32 | 18 | Q Does the largest footprint also include |
| 11:27:11 11:27:14 | 19 20 | Q And what do you mean by "maximize the implant footprint"? | 11:30:35 11:30:39 | 19 20 | increasing the surface area for fusion or maximizing the surface area for fusion? |
| 11:27:14 | 20 | footprint"? A To make for the largest possible implant | 11:30:39 | 20 | MR. MILLER: Objection; vague. |
| 11:27:19 | 22 | delivered. | 11:30:41 | 22 | THE WITNESS: Please repeat the question. |
| 11:27:21 | 23 | Q And is it your understanding that the largest | 11:30:44 | 23 | BY MS. WICKRAMASEKERA: |
| 11:27:25 | 24 | possible implant delivered should rest on the cortical | 11:30:48 | 24 | Q When you testified that the CoRoent XL-Standard |
| 11:27:29 | 25 | ring of the vertebra? | 11:30:54 | 25 | was designed to provide the largest footprint, implant |
| Mozazaill | Con | · · | Mozara i 1 1 | Con | |
| Merrill 800-826-027 | | poration - Los Angeles www.merrillcorp.com/law | Merrill 800-826-027 | | poration - Los Angeles www.merrillcorp.com/law |
| CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 | | 1 | | | |
| | | | | | RMATION - PATENT PROSECUTION SENSITIVE MILES - 11/8/2010 |
| | | | PAT | | |
| | | MILES - 11/8/2010 | PAT | | MILES - 11/8/2010 |
| PATE | RICK | MILES - 11/8/2010 Page 42 | PAT | RICK | MILES - 11/8/2010 Page 44 |
| PATF | RICK | MILES - 11/8/2010 Page 42 MR. MILLER: Objection; calls for expert | PAT: | RICK | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the |
| PATF 11:27:31 11:27:32 | RICK | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. | PAT: | RICK | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? |
| PATE 11:27:31 11:27:32 11:27:38 | 1 2 3 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. | PAT: 11:31:01 11:31:05 11:31:17 | 1 2 3 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. |
| PATE 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 | 1 2 3 4 5 6 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to | PAT: 11:31:01 11:31:05 11:31:17 11:31:24 | 1 2 3 4 5 6 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? |
| PATE 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 | 1 2 3 4 5 6 7 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? | PAT: 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 | 1 2 3 4 5 6 7 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my |
| PATE 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 | 1 2 3 4 5 6 7 8 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. | PAT: 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 | 1 2 3 4 5 6 7 8 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. |
| PATE 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 | 1 2 3 4 5 6 7 8 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the | PAT: 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 | 1 2 3 4 5 6 7 8 9 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is |
| PATE 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 | 1 2 3 4 5 6 7 8 9 10 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. | PAT: 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 | 1 2 3 4 5 6 7 8 9 10 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent |
| PATE 11:27:31 11:27:32 11:27:38 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 | 1 2 3 4 5 6 7 8 9 10 11 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 | 1 2 3 4 5 6 7 8 9 10 11 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the |
| PATE 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 | 1 2 3 4 5 6 7 8 9 10 11 12 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? |
| PATE 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 | 1 2 3 4 5 6 7 8 9 10 11 12 13 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:54 11:31:54 11:31:58 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert |
| PATE 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 | 1 2 3 4 5 6 7 8 9 10 11 12 | MILES - 11/8/2010 Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:24 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:58 11:31:59 11:32:01 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 | Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:24 11:28:26 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:58 11:31:59 11:32:01 11:32:04 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:24 11:28:26 11:28:30 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:54 11:31:54 11:31:58 11:31:59 11:32:01 11:32:04 11:32:06 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:24 11:28:26 11:28:30 11:28:30 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:58 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 | Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:24 11:28:26 11:28:30 11:28:30 11:28:32 11:28:40 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the body of the of the vertebra. | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 11:32:08 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 | Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. BY MS. WICKRAMASEKERA: |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:24 11:28:26 11:28:30 11:28:30 11:28:32 11:28:40 11:28:44 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 | MILES - 11/8/2010 Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the body of the of the vertebra. Q Anything else? | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 11:32:08 11:32:09 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 | Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. BY MS. WICKRAMASEKERA: Q On what? |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:24 11:28:26 11:28:30 11:28:30 11:28:44 11:28:44 11:28:44 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 | MILES - 11/8/2010 Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the body of the of the vertebra. Q Anything else? A How to revise it. | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:54 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 11:32:08 11:32:09 11:32:09 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 | Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. BY MS. WICKRAMASEKERA: Q On what? A Bone quality, type of application, density of |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:24 11:28:30 11:28:30 11:28:30 11:28:30 11:28:30 11:28:30 11:28:30 11:28:30 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 | MILES - 11/8/2010 Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the body of the of the vertebra. Q Anything else? A How to revise it. Q And just for the record, can you explain what | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:58 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 11:32:08 11:32:09 11:32:09 11:32:09 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 | Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. BY MS. WICKRAMASEKERA: Q On what? A Bone quality, type of application, density of bone, surgical technique. |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:03 11:28:08 11:28:44 11:28:56 11:28:40 11:28:56 11:28:58 11:29:00 11:29:05 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the body of the of the vertebra. Q Anything else? A How to revise it. Q And just for the record, can you explain what you mean by "revise"? A If you had to take it out. Q Anything else? | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:58 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 11:32:08 11:32:09 11:32:09 11:32:22 11:32:35 11:32:48 11:32:52 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 | Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. BY MS. WICKRAMASEKERA: Q On what? A Bone quality, type of application, density of bone, surgical technique. Q Anything else? A Not to my knowledge. Q Now, when you say it depends on type of |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:08 11:28:24 11:28:26 11:28:30 11:28:30 11:28:40 11:28:40 11:28:50 11:28:50 11:28:56 11:28:58 11:29:00 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the body of the of the vertebra. Q Anything else? A How to revise it. Q And just for the record, can you explain what you mean by "revise"? A If you had to take it out. | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:58 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 11:32:08 11:32:09 11:32:09 11:32:22 11:32:35 11:32:48 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. BY MS. WICKRAMASEKERA: Q On what? A Bone quality, type of application, density of bone, surgical technique. Q Anything else? A Not to my knowledge. |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:08 11:28:08 11:28:24 11:28:26 11:28:30 11:28:30 11:28:40 11:28:40 11:28:50 11:28:50 11:28:50 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 | MILES - 11/8/2010 Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the body of the of the vertebra. Q Anything else? A How to revise it. Q And just for the record, can you explain what you mean by "revise"? A If you had to take it out. Q Anything else? A Nothing other than normal contouring type of | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:58 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 11:32:08 11:32:09 11:32:09 11:32:22 11:32:35 11:32:48 11:32:52 | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 | MILES - 11/8/2010 Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. BY MS. WICKRAMASEKERA: Q On what? A Bone quality, type of application, density of bone, surgical technique. Q Anything else? A Not to my knowledge. Q Now, when you say it depends on type of application, what are you referring to? |
| 11:27:31 11:27:32 11:27:38 11:27:39 11:27:40 11:27:43 11:27:48 11:27:51 11:28:00 11:28:01 11:28:02 11:28:03 11:28:03 11:28:08 11:28:24 11:28:26 11:28:30 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 COr | Page 42 MR. MILLER: Objection; calls for expert testimony, beyond the scope of topic 2. THE WITNESS: Repeat the question, please. BY MS. WICKRAMASEKERA: Q Actually, I'll ask you a different question. Did NuVasive design the CoRoent XL-Standard to rest on the cortical ring of the vertebra? MR. MILLER: Objection; vague. THE WITNESS: I recall that to be one of the design requirements. BY MS. WICKRAMASEKERA: Q What were the other design requirements for determining the length of the CoRoent XL-Standard? A How that it would sit on the body of the vertebra. Q What do you mean by that? A How it would be positioned as it relates to the body of the of the vertebra. Q Anything else? A How to revise it. Q And just for the record, can you explain what you mean by "revise"? A If you had to take it out. Q Anything else? | 11:31:01 11:31:05 11:31:17 11:31:24 11:31:27 11:31:33 11:31:42 11:31:46 11:31:49 11:31:51 11:31:54 11:31:58 11:31:59 11:32:01 11:32:04 11:32:06 11:32:07 11:32:08 11:32:09 11:32:09 11:32:09 11:32:09 11:32:09 11:32:54 Merrill | RICK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Cor | Page 44 footprint, are you also referring to maximizing the surface area for fusion? A Yes. It's one of several values that that has. Q And what are the other values? A Minimizing subsidence. Q Anything else? A I'm sure there's multiple. Off the top of my head, no. Q Now, with respect to minimizing subsidence, is it your understanding that in order for the CoRoent XL-Standard to minimize subsidence, it must rest on the cortical ring? MR. MILLER: Objection; calls for expert testimony, beyond the scope of the noticed topics. To the extent you can answer in your individual capacity, you may. THE WITNESS: It depends. BY MS. WICKRAMASEKERA: Q On what? A Bone quality, type of application, density of bone, surgical technique. Q Anything else? A Not to my knowledge. Q Now, when you say it depends on type of |

CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 46 11:34:04 any way disrupts the end plate, it will affect it. 11:34:33 Q How did NuVasive -- during the design of the 11:34:38 CoRoent XL-Standard, how did NuVasive come up 11:34:41 specifically with the lengths 40 and 45? 11:34:49 MR. MILLER: Objection; asked and answered. 11:34:51 Go ahead, tell her again. 11:34:55 THE WITNESS: How did we come up with them? 11:34:58 We -- trying to maximize the surface area, and so it was 11:35:07 guessed that 40 and 45 would accommodate the maximal 11:35:12 10 surface area. 11:35:13 BY MS. WICKRAMASEKERA: 11:35:13 Q The maximum surface area of what? 11:35:18 13 A Of the vertebral body. 11:35:20 Q Whose vertebral body? 14 11:35:23 15 A An average population. 11:35:31 16 Q What percentage of the average population? 11:35:33 17 MR. MILLER: Objection; calls for expert 11:35:36 18 testimony, beyond the scope of topic 2. 11:35:38 19 THE WITNESS: Please repeat the question. BY MS. WICKRAMASEKERA: 11:35:40 2.0 11:35:45 21 Q When NuVasive designed the CoRoent XL to come 11:35:51 2.2 in 40 and 45 millimeters of length, what percentage of 11:35:57 23 the average population was the CoRoent XL designed for? 11:36:04 24 MR. MILLER: Objection; calls for expert 11:36:07 opinion, beyond the scope of topic 2. Merrill _ Los Angeles Corporation 800-826-0277 www.merrillcorp.com/law

| | | | CONFIDENTI | AT TMEO | PRMATION - PATENT PROSECUTION SENSITIVE |
|--|--|---|----------------------|----------|--|
| | | | | | MILES - 11/8/2010 |
| | | | | | |
| | | | | | Page 51 |
| | | | 11:41:33 | 1 | A I specifically don't recall. |
| | | | 11:41:35 | 2 | Q And what was the feedback? |
| | | | 11:41:41 | 3 | A That 18 would accommodate a neurologic aperture |
| | | | 11:41:48 11:41:54 | 4 5 | to deliver the largest possible footprint. Q And what do you mean by neurologic aperture? |
| | | | 11:42:00 | 6 | A The distance between neural elements. |
| | | | 11:42:16 | 7 | Q And where are these neural elements that you're |
| | | | 11:42:18 | 8 | referring to located? |
| | | | 11:42:21 | 9 | MR. MILLER: Objection; beyond the scope of |
| | | | 11:42:22 | 10 | topic 2, calls for expert testimony. |
| | | | 11:42:27 11:42:28 | 11 12 | THE WITNESS: Please repeat the question. BY MS. WICKRAMASEKERA: |
| | | | 11:42:29 | 13 | Q And where are the neural elements that you're |
| | | | 11:42:31 | 14 | referring to located? |
| | | | 11:42:36 | 15 | A In the human body. |
| | | | 11:42:38 | 16 | Q Can you be any more specific? |
| | | | 11:42:40 | 17 | A Yes. |
| | | | 11:42:41 | 18 | Q Please do so. |
| | | | 11:42:42 11:43:04 | 19 20 | A In the psoas muscle. Q So when you testified that the surgeon feedback |
| | | | 11:43:04 | 20 | was that an 18-millimeter wide CoRoent XL-Standard would |
| | | | 11:43:11 | 22 | accommodate the neurological aperture to deliver the |
| | | | 11:43:16 | 23 | largest possible implant, are you specifically referring |
| | | | 11:43:23 | 24 | to an incision in the psoas muscle? |
| | | | 11:43:32 | 25 | MR. MILLER: Objection; mischaracterizes |
| | | | Merrill | | rporation - Los Angeles |
| | | | 800-826-027 | 77 | www.merrillcorp.com/law |
| CONFIDENTIA | AL INFO | RMATION - PATENT PROSECUTION SENSITIVE | | | |
| | | MILES - 11/8/2010 | | | |
| | | . MITTE2 - TI/0/70IO | | | |
| | | | | | |
| | | Page 5 | 0 | | |
| 11:40:17 | 1 | Page 5 Q Now, when you say it depends upon how they | 0 | | |
| 11:40:20 | 2 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement | 0 | | |
| 11:40:20 11:40:22 | 2 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? | 0 | | |
| 11:40:20 | 2 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. | 0 | | |
| 11:40:20 11:40:22 11:40:26 | 2 3 4 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:30 11:40:33 | 2 3 4 5 6 7 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:33 | 2 3 4 5 6 7 8 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 | 2 3 4 5 6 7 8 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 | 2 3 4 5 6 7 8 9 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 | 2 3 4 5 6 7 8 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 | 2 3 4 5 6 7 8 9 10 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 | 2 3 4 5 6 7 8 9 10 11 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 | 2 3 4 5 6 7 8 9 10 11 12 13 14 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 11:40:48 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 11:40:48 11:40:51 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 11:40:48 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. BY MS. WICKRAMASEKERA: | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 11:40:48 11:40:51 11:40:52 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 11:40:48 11:40:51 11:40:52 11:41:01 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. BY MS. WICKRAMASEKERA: Q What was the first width that the CoRoent | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 11:40:51 11:40:52 11:41:01 11:41:04 11:41:07 11:41:14 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. BY MS. WICKRAMASEKERA: Q What was the first width that the CoRoent XL-Standard was available in? A 18. Q How did NuVasive determine that the CoRoent | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:42 11:40:42 11:40:47 11:40:47 11:40:51 11:40:52 11:41:01 11:41:04 11:41:07 11:41:14 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. BY MS. WICKRAMASEKERA: Q What was the first width that the CoRoent XL-Standard was available in? A 18. Q How did NuVasive determine that the CoRoent XL-Standard should be designed in 18-millimeter width? | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 11:40:51 11:40:52 11:41:01 11:41:04 11:41:07 11:41:15 11:41:25 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. BY MS. WICKRAMASEKERA: Q What was the first width that the CoRoent XL-Standard was available in? A 18. Q How did NuVasive determine that the CoRoent XL-Standard should be designed in 18-millimeter width? A Through surgeon feedback. | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:47 11:40:47 11:40:48 11:40:51 11:40:52 11:41:01 11:41:04 11:41:07 11:41:14 11:41:25 11:41:26 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. BY MS. WICKRAMASEKERA: Q What was the first width that the CoRoent XL-Standard was available in? A 18. Q How did NuVasive determine that the CoRoent XL-Standard should be designed in 18-millimeter width? A Through surgeon feedback. Q Which surgeons? | | | |
| 11:40:20 11:40:22 11:40:26 11:40:30 11:40:33 11:40:35 11:40:35 11:40:37 11:40:39 11:40:42 11:40:46 11:40:47 11:40:47 11:40:51 11:40:52 11:41:01 11:41:04 11:41:07 11:41:15 11:41:25 | 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 | Page 5 Q Now, when you say it depends upon how they applied the device, are you referring to the placement of the device on the vertebra? A Yes. Q And MR. MILLER: Move to interpose, the question is beyond the scope of topic 2. THE WITNESS: Sorry. MR. MILLER: That's all right. My delay. BY MS. WICKRAMASEKERA: Q And when you when you testified that it depends on what for, are you referring to the diagnosis or indication? A Yes. MR. MILLER: Same objection. That time it was your fault. Slow down just a little bit. BY MS. WICKRAMASEKERA: Q What was the first width that the CoRoent XL-Standard was available in? A 18. Q How did NuVasive determine that the CoRoent XL-Standard should be designed in 18-millimeter width? A Through surgeon feedback. | | | |

CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 71 12:20:56 1 THE WITNESS: I guess I don't know what you're 12:20:58 2 getting at. If an implant is 3 feet large and a patient 12:21:07 is 2 feet, then likely it would -- you'd have to split 12:21:11 the patient in half to get it in. 12:21:14 BY MS. WICKRAMASEKERA: 12:21:15 Q As a designer of the CoRoent XL-Standard, would 12:21:17 you consider an implant that's 35 millimeters wide too 12:21:21 wide to be used in an XLIF procedure? 12:21:24 MR. MILLER: Objection; calls for expert 12:21:26 10 testimony, beyond the scope of topic 2, lacks 12:21:30 foundation, calls for speculation, vague. 11 12:21:33 12 THE WITNESS: It didn't come up as a 12:21:36 13 requirement to reflect the needs of the surgery, so I don't recall its contemplation. 12:21:40 14 BY MS. WICKRAMASEKERA: 12:21:42 15 12:21:46 16 Q Was the CoRoent XL-Standard designed initially 12:21:51 17 as a vertebral body replacement device? 12:22:04 18 A The -- the original design requirement was --12:22:11 19 was what I discussed before which was to maximize the 12:22:23 20 footprint on the vertebral body. 12:22:24 21 Q Was the CoRoent XL-Standard designed as an 12:22:25 22 interbody fusion device then? 12:22:31 23 A It was designed to restore stability and 12:22:37 24 restore vertebral body height. 12:22:57 25 Q Do you have any understanding as to whether the Merrill Corporation Los Angeles 800-826-0277 www.merrillcorp.com/law

CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 75 12:27:42 1 BY MS. WICKRAMASEKERA: 12:27:45 2 Q Was the CoRoent XL-Standard implant designed to 12:27:48 be used as a total vertebral body replacement? 12:27:58 A I'm unfamiliar with what a total vertebral body 12:28:01 replacement is. 12:28:17 Q What material is the CoRoent XL-Standard made 12:28:20 7 of? 12:28:24 8 A PolyEtherEther-Ketone. 12:28:27 Q And why did NuVasive choose this material when 12:28:30 10 designing the CoRoent XL implant? 12:28:33 11 A Because it was of similar biomechanical nature 12:28:39 12 as bone. 12:28:50 13 Q Do you have any understanding as to why 12:28:52 14 NuVasive sought clearance of the CoRoent XL as a 12:28:55 vertebral body replacement? 15 12:28:59 MR. MILLER: I'm sorry, could you repeat the 16 17 12:29:01 question. 12:29:02 18 (Record read as follows: 12:29:10 19 "Q Do you have any understanding as to 12:29:10 20 why NuVasive sought clearance of the CoRoent XL 12:29:10 21 as a vertebral body replacement?") 12:29:12 22 MR. MILLER: Objection; beyond the scope of 12:29:14 23 topic 2, asks for expert testimony, assumes facts not in 12:29:21 24 12:29:25 25 THE WITNESS: And I should say partial Merrill Corporation Los Angeles 800-826-0277 www.merrillcorp.com/law CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 76 12:29:27 vertebral body replacement. So yes. BY MS. WICKRAMASEKERA: 12:29:31 12:29:32 3 Q And what is your understanding? 12:29:34 MR. MILLER: Same objections. 12:29:35 THE WITNESS: That it would be used in that 12:29:36 6 application. 12:29:37 BY MS. WICKRAMASEKERA: 12:29:39 8 Q So is it your understanding that NuVasive 12:29:41 sought clearance to use a CoRoent XL implant as a 12:29:44 10 partial body replacement? 12:29:47 11 MR. MILLER: Same objections, beyond the scope. 12:29:49 12 THE WITNESS: Yes. BY MS. WICKRAMASEKERA: 12:29:49 13 Q And what is your understanding of what a 12:29:51 14 12:29:53 15 partial vertebral body replacement is? 12:29:57 16 MR. MILLER: Same objections. 12:30:00 17 THE WITNESS: A partial vertebral body is a --12:30:03 18 a partial vertebral body replacement removes part of the 12:30:08 19 vertebra and replaces it with an implant. BY MS. WICKRAMASEKERA: 12:30:11 20 12:30:13 21 Q Now, why did you distinguish between a partial 12:30:15 22 vertebral body replacement and a total vertebral body 12:30:19 23 replacement? 12:30:20 24 MR. MILLER: Same objections. THE WITNESS: I'm unfamiliar with the 12:30:28 Merrill Corporation -Los Angeles 800-826-0277 www.merrillcorp.com/law

```
CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE
         PATRICK MILES - 11/8/2010
                                                              Page 81
    12:35:38
                    1
                         clearance for as a partial vertebral body replacement,
   12:35:41
                     2
                         did you consider whether the CoRoent XL implant could be
   12:35:48
                    3
                         used as a vertebral body replacement?
                              MR. MILLER: Objection; beyond the scope of
   12:35:51
   12:35:53
                         topic 2, calls for expert testimony, assumes facts not
   12:35:57
                         in evidence, lacks foundation, calls for speculation,
   12:36:01
                         vague, overbroad, incomprehensible.
   12:36:07
                         BY MS. WICKRAMASEKERA:
   12:36:07
                           O Go ahead.
   12:36:10
                   10
                           A I don't understand the question.
                           Q You testified that the CoRoent XL-Standard --
   12:36:11
                   11
   12:36:13
                   12
                         withdrawn.
   12:36:14
                   13
                              You testified that NuVasive had at some point
   12:36:17
                         sought clearance from the FDA for the CoRoent
                   14
   12:36:22
                   15
                         XL-Standard to be used as a partial vertebral body
   12:36:26
                   16
                         replacement; is that correct?
   12:36:29
                   17
                           A Can you read back exactly what I said?
   12:36:33
                   18
                           Q Do you know the answer to the question?
   12:36:36
                   19
                           A You asked if I testified to the fact, and I'm
   12:36:39
                    20
                         asking you to read back what I said which would
   12:36:43
                    21
                         accommodate, you know, us agreeing on what I stated.
   12:36:45
                    22
                           Q Sure. Let's just ask the question again.
   12:36:49
                    23
                              Did NuVasive at any point seek clearance from
   12:36:51
                    24
                         the FDA for the CoRoent XL-Standard to be used as a
    12:36:55
                    25
                         partial vertebral body replacement?
Merrill
                  Corporation
                                                   Los Angeles
800-826-0277
                                      www.merrillcorp.com/law
    CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE
         PATRICK MILES - 11/8/2010
                                                              Page 82
   12:36:58
                              MR. MILLER: Objection; beyond the scope of
   12:36:59
                         topic 2.
   12:37:00
                              THE WITNESS: Yes.
   12:37:00
                         BY MS. WICKRAMASEKERA:
   12:37:03
                           Q When designing the CoRoent XL implant for use
   12:37:06
                         as a partial vertebral body replacement, did NuVasive
   12:37:17
                         consider whether the CoRoent XL implant could also be
   12:37:18
                         used as a vertebral body replacement?
   12:37:21
                              MR. MILLER: Objection; beyond the scope of
   12:37:23
                   10
                         topic 2, lacks foundation, calls for speculation, vague.
   12:37:31
                   11
                              THE WITNESS: Can you repeat the specific
   12:37:32
                   12
                         question?
                         BY MS. WICKRAMASEKERA:
   12:37:32
                   13
   12:37:33
                   14
                            O Sure. Actually, let me rephrase the question.
   12:37:40
                   15
                              Did NuVasive consider whether the CoRoent XL
   12:37:43
                   16
                         implant could be used as a vertebral body replacement?
   12:37:47
                   17
                              MR. MILLER: Same objections.
   12:37:49
                   18
                              THE WITNESS: At what point in time?
                         BY MS. WICKRAMASEKERA:
   12:37:50
                   19
   12:37:51
                   2.0
                           Q At any point.
   12:37:53
                   21
                              MR. MILLER: Same objections.
   12:38:01
                   22
                              THE WITNESS: When we -- repeat the question
   12:38:04
                   23
                         again.
   12:38:05
                   2.4
                         BY MS. WICKRAMASEKERA:
   12:38:09
                            Q Did NuVasive at any point consider whether the
                                           _
Merrill
                  Corporation
                                                   Los Angeles
800-826-0277
                                      www.merrillcorp.com/law
```

```
CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE
        PATRICK MILES - 11/8/2010
                                                           Page 85
   12:41:34
                        see around it. I guess I said that, profile. Off the
   12:41:40
                        top of my head, fundamentally that's it.
   12:41:43
                        BY MS. WICKRAMASEKERA:
   12:41:48
                          Q When NuVasive was designing the CoRoent XL
   12:41:51
                        implant and the tools for inserting the CoRoent XL
   12:41:55
                        implant, did NuVasive specifically have the lateral
   12:41:58
                        approach in mind?
   12:41:59
                          A For the CoRoent XL?
   12:42:01
                          Q Yes.
   12:42:02
                  10
                          A Yes.
   12:42:04
                          Q Could the CoRoent XL be inserted using an
                  11
   12:42:11
                  12
                        approach other than XLIF?
   12:42:14
                  13
                            MR. MILLER: Objection; beyond the scope of
   12:42:18
                  14
                        topic 2, calls for speculation, calls for expert
   12:42:21
                  15
                        testimony, lacks foundation, calls for speculation.
   12:42:26
                  16
                            THE WITNESS: Yes.
   12:42:26
                  17
                        BY MS. WICKRAMASEKERA:
   12:42:27
                  18
                          Q What other approaches can the CoRoent XL be
   12:42:30
                  19
                        used for?
   12:42:31
                  20
                            MR. MILLER: Same objections.
   12:42:36
                  21
                            THE WITNESS: Anteriorly.
   12:42:39
                  22
                        BY MS. WICKRAMASEKERA:
   12:42:40
                  23
                          Q Any other approaches?
   12:42:42
                  24
                          A Safely. Are you asking safely or any other
   12:42:47
                  25
                        approaches?
Merrill
                 Corporation
                                                Los Angeles
800-826-0277
                                    www.merrillcorp.com/law
   CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE
        PATRICK MILES - 11/8/2010
                                                           Page 86
   12:42:48
                          Q Any other approaches.
   12:42:49
                          A It can be put in for several different types of
   12:42:53
                        approaches. The question is, do you want to do it
   12:42:56
                        safely or not.
   12:42:57
                          Q I see. Well, let's run through the list of
   12:43:00
                        approaches first.
   12:43:02
                            Can the CoRoent XL implant be inserted
   12:43:03
                        anteriorly?
   12:43:05
                          A Yes.
   12:43:05
                  10
                          O Can it be inserted --
   12:43:06
                  11
                            MR. MILLER: Pause.
   12:43:07
                  12
                            THE WITNESS: Sorry.
   12:43:07
                        BY MS. WICKRAMASEKERA:
                  13
   12:43:07
                          Q Can the CoRoent XL implant be inserted using a
                  14
   12:43:13
                  15
                        PLIF?
   12:43:14
                  16
                            MR. MILLER: Objection. It's beyond the scope
   12:43:15
                  17
                        of the topics, calls for expert testimony, vague,
   12:43:19
                  18
                        overbroad as well
                            Go ahead
   12:43:20
                  19
                            THE WITNESS: Yes.
                  2.0
   12:43:21
                        BY MS. WICKRAMASEKERA:
   12:43:21
                  21
   12:43:23
                  22
                          Q Can a CoRoent XL-Standard be inserted using
   12:43:27
                  23
                        TLIF procedure?
   12:43:32
                  24
                            MR. MILLER: Same objections.
   12:43:32
                            THE WITNESS: Yes.
Merrill
                 Corporation
                                          _
                                                Los Angeles
800-826-0277
                                    www.merrillcorp.com/law
```

CONFIDENTIAL INFORMATION - PATENT PROSECUTION SENSITIVE PATRICK MILES - 11/8/2010 Page 165 15:28:24 1 with the TLIF procedure? MR. MILLER: Objection; incomprehensible, 15:28:27 2 15:28:29 3 vague, beyond the scope. 15:28:31 4 MS. WICKRAMASEKERA: Actually, I withdraw the 15:28:33 5 question. 15:28:34 Q Does NuVasive market the CoRoent XL for use in 15:28:37 the XLIF as a significantly bigger cage than the cage 15:28:43 that can be used with the TLIF procedure? 15:28:49 A Yes, generally speaking. 15:29:07 10 Q Does the CoRoent XL implant have apertures in 15:29:11 11 it? 15:29:12 12 MR. MILLER: Objection; vague, calls for a 15:29:16 13 legal conclusion. Just a moment. 15:29:23 14 Beyond the scope, at least topic 3 which is 15:29:30 15 where we were just at. 15:29:40 16 THE WITNESS: If you're asking me if there's 15:29:42 17 holes in the cage, there are, yes. 15:29:44 18 BY MS. WICKRAMASEKERA: 15:29:44 19 Q What's that I'm asking. 15:29:45 20 What is the purpose of the openings in the 15:29:48 21 cage? 15:29:50 22 MR. MILLER: Objection; beyond the scope. 15:29:54 23 THE WITNESS: They are for the application of 15:30:02 24 biologic material, be it allograft, to provide for 15:30:12 25 predictable fusion environment. Merrill Corporation Los Angeles 800-826-0277 www.merrillcorp.com/law